PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges

Immunotherapy. 2019 Oct;11(15):1267-1271. doi: 10.2217/imt-2019-0146. Epub 2019 Sep 9.
No abstract available

Keywords: actinium-225 (225Ac); lutetium-177 (177Lu); metastatic castration-resistant prostate cancer (mCRPC); prostate-specific membrane antigen (PSMA); radioligand therapy (RLT).

Publication types

  • Editorial

MeSH terms

  • Antigens, Surface*
  • Glutamate Carboxypeptidase II*
  • Humans
  • Lutetium / therapeutic use*
  • Male
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Radioimmunotherapy / methods*
  • Radioisotopes / therapeutic use*
  • Radiopharmaceuticals / therapeutic use*

Substances

  • Antigens, Surface
  • Radioisotopes
  • Radiopharmaceuticals
  • Lutetium
  • Lutetium-177
  • FOLH1 protein, human
  • Glutamate Carboxypeptidase II